Brain Imaging Study of DSP-2342 in People with Schizophrenia
Tests a new drug, DSP-2342, on brain function in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: Brain Imaging of DSP-2342
Key facts
- Where
- Baltimore, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07850102, who can take part
Where in United States
- Johns Hopkins UniversityBaltimore, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT07850102
- Record updated
- 30 September 2026
- Original description
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.Read full original descriptionShow less
Brain Imaging of DSP-2342
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.
Inclusion: right-handed, participants with schizophrenia between the ages of 18-50 years.
Exclusion: Having a contraindication to MRI, including a pacemaker, defibrillator or other medical implant, other metal objects, or claustrophobia, or for having braces or other metal in the head region (likely to create an artifact on the MRI scans); Medication changes in the past six weeks; Subjects with renal impairment; Subjects with hepatic impairment; Past or current neurological disorder (including stroke, brain tumor, epilepsy, Alzheimer's, Parkinson's or Huntington's disease); Non-schizophrenia cause of cognitive impairment; Uncontrolled medical disorder that may interfere with cognition or compromise safety; Head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma; Recent history of electroconvulsive therapy; Subjects with electrocardiographic abnormalities (particularly QTc prolongation); Current substance misuse; Pregnancy or breast feeding; Significant suicidal ideation.